COASY

COASY Full Name

CoA synthase

COASY Introduction

CoA synthase (COASY) is a bifunctional enzyme that catalyzes the final two steps of coenzyme A (CoA) biosynthesis from pantothenate (vitamin B5). Encoded by the COASY gene on chromosome 17q21.2, this enzyme uniquely combines two distinct enzymatic activities within a single polypeptide: 4'-phosphopantetheine adenylyltransferase (PPAT) activity at its N-terminal domain and dephospho-CoA kinase (DPCK) activity at its C-terminal domain. CoA is an essential cofactor involved in over 100 biochemical reactions, including the tricarboxylic acid (TCA) cycle, fatty acid synthesis and oxidation, and post-translational protein acetylation, making COASY indispensable for cellular metabolism.

Figure 1. COASY binding assay.

Bifunctional Catalytic Mechanism and Regulation
COASY sequentially converts 4'-phosphopantetheine to dephospho-CoA (via PPAT activity) and then phosphorylates dephospho-CoA to produce CoA (via DPCK activity). The PPAT domain catalyzes the magnesium-dependent reversible transfer of an adenylyl group from ATP to 4'-phosphopantetheine, releasing pyrophosphate, while the DPCK domain uses ATP to phosphorylate the 3'-hydroxyl group of the ribose moiety in dephospho-CoA. COASY localizes to the mitochondrial matrix and is associated with the inner mitochondrial membrane, where it may be positioned to channel newly synthesized CoA directly to metabolic enzyme complexes. The DPCK domain of human COASY shares structural homology with the nucleotide kinase superfamily, and mutations affecting either catalytic domain can cause CoA deficiency syndromes. Expression of COASY is regulated by the PPARα nuclear receptor, linking CoA biosynthesis to lipid metabolism and energy homeostasis.

COASY Protein-Associated Neurodegeneration (CoPAN) and Metabolic Disorders
Biallelic mutations in COASY cause COASY protein-associated neurodegeneration (CoPAN), a rare autosomal recessive disorder belonging to the neurodegeneration with brain iron accumulation (NBIA) spectrum. CoPAN patients present with early-onset spastic-dystonic paraparesis, oromandibular dystonia, dysarthria, cognitive impairment, and progressive motor decline. Neuroimaging reveals characteristic iron deposition in the globus pallidus and substantia nigra, along with T2-weighted hyperintensities. The pathophysiological mechanism involves impaired CoA biosynthesis leading to mitochondrial dysfunction, disturbed lipid metabolism, and defective iron-sulfur cluster biogenesis in neurons. Currently, CoPAN has no disease-modifying therapy; treatment is symptomatic. Research efforts are focused on CoA precursor supplementation strategies (e.g., pantethine, 4'-phosphopantetheine) and gene therapy approaches for restoring CoA homeostasis in affected neurons.

Alternate Names for COASY

COASY; CoA synthase; NBP; DPCK; PPAT; UKR1; NBIA6; pOV-2; bifunctional coenzyme A synthase; nucleotide binding protein; phosphopantetheine adenylyltransferase / dephosphocoenzyme A kinase; bifunctional phosphopantetheine adenylyl transferase/dephospho CoA kinase;